Gonal-F

Gonal-F contains the active ingredient follitropin alfa, a synthetic follicle-stimulating hormone, supplied as an injection solution for subcutaneous use. It is a prescription medication marketed in the European Union for fertility and reproductive endocrinology indications. The product is administered by injection and is classified as a gonadotropin (FSH) analog, indicated for controlled ovarian stimulation, anovulation treatment, and selected cases of male infertility in adults under specialist supervision.

Gonal-F is prescribed for several fertility-related conditions where stimulation of follicle-stimulating hormone pathways is required.

- Induction of ovulation in women with anovulatory disorders such as polycystic ovary syndrome. - Controlled ovarian stimulation for assisted reproductive technologies including in-vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI). - Treatment of hypogonadotropic hypogonadism to restore normal gonadal function. - Management of male infertility associated with low endogenous FSH levels to support spermatogenesis. - Support of follicular development in women undergoing donor egg cycles. - Use in combination with luteinising hormone analogues for multifollicular growth in certain protocols.

The safety profile of Gonal-F reflects its pharmacologic activity on the reproductive axis; side effects are reported in clinical use and may vary in frequency.

Common: - Injection site reactions such as redness, swelling, or mild pain. - Headache or mild dizziness. - Abdominal discomfort or bloating. - Mood changes including irritability or mild anxiety. - Nausea or mild vomiting. - Fatigue or decreased energy.

Serious: - Ovarian hyperstimulation syndrome (OHSS) presenting with rapid weight gain, abdominal distension, or shortness of breath. - Multiple pregnancy (twins, triplets, etc.) due to overstimulation. - Severe allergic reaction (anaphylaxis) with rash, swelling, or difficulty breathing. - Thromboembolic events, though rare, such as deep vein thrombosis. - Ovarian cyst formation that may require monitoring. - Severe abdominal pain indicating possible ovarian torsion.

When prescribing Gonal-F, clinicians consider several precautionary measures to minimise risks and ensure appropriate patient selection.

- Confirm diagnosis of infertility and assess baseline hormone levels before initiating therapy. - Evaluate for contraindications such as ovarian cysts, uncontrolled thyroid disease, or active malignancy. - Monitor ovarian response with ultrasound and estradiol measurements to detect excessive stimulation. - Adjust dose based on individual response and avoid over-dosage. - Counsel patients on recognizing symptoms of ovarian hyperstimulation syndrome and when to seek medical attention. - Use caution in patients with a history of thromboembolic events or cardiovascular disease. - In men, assess baseline sperm parameters and FSH levels before treatment.

Gonal-F may interact with other medications or substances that affect hormonal balance, ovarian response, or coagulation pathways.

Avoid: - Concurrent use of other gonadotropins or high-dose estrogen preparations that could exacerbate ovarian stimulation. - Medications known to increase the risk of thromboembolism, such as hormonal contraceptives containing estrogen, during treatment.

Use with caution: - Anticoagulant therapy (e.g., warfarin, direct oral anticoagulants) because of the potential for altered clotting risk in cases of ovarian hyperstimulation. - Thyroid hormone replacement or antithyroid drugs, requiring monitoring of thyroid function during therapy. - Non-steroidal anti-inflammatory drugs (NSAIDs) that may affect prostaglandin synthesis and uterine contractility. - Any medication that influences the hypothalamic-pituitary-gonadal axis, such as GnRH analogues, should be coordinated with the treating specialist.